APA 6th Edition Lazić, R., Boras, I., Vlašić, M., Gabrić, N. i Tomić, Z. (2010). Anti-VEGF in Treatment of Central Retinal Vein Occlusion. Collegium antropologicum, 34 supplement 2 (2), 69-72. Preuzeto s https://hrcak.srce.hr/51632
MLA 8th Edition Lazić, Ratimir, et al. "Anti-VEGF in Treatment of Central Retinal Vein Occlusion." Collegium antropologicum, vol. 34 supplement 2, br. 2, 2010, str. 69-72. https://hrcak.srce.hr/51632. Citirano 17.06.2021.
Chicago 17th Edition Lazić, Ratimir, Ivan Boras, Marko Vlašić, Nikica Gabrić i Zoran Tomić. "Anti-VEGF in Treatment of Central Retinal Vein Occlusion." Collegium antropologicum 34 supplement 2, br. 2 (2010): 69-72. https://hrcak.srce.hr/51632
Harvard Lazić, R., et al. (2010). 'Anti-VEGF in Treatment of Central Retinal Vein Occlusion', Collegium antropologicum, 34 supplement 2(2), str. 69-72. Preuzeto s: https://hrcak.srce.hr/51632 (Datum pristupa: 17.06.2021.)
Vancouver Lazić R, Boras I, Vlašić M, Gabrić N, Tomić Z. Anti-VEGF in Treatment of Central Retinal Vein Occlusion. Collegium antropologicum [Internet]. 2010 [pristupljeno 17.06.2021.];34 supplement 2(2):69-72. Dostupno na: https://hrcak.srce.hr/51632
IEEE R. Lazić, I. Boras, M. Vlašić, N. Gabrić i Z. Tomić, "Anti-VEGF in Treatment of Central Retinal Vein Occlusion", Collegium antropologicum, vol.34 supplement 2, br. 2, str. 69-72, 2010. [Online]. Dostupno na: https://hrcak.srce.hr/51632. [Citirano: 17.06.2021.]
Sažetak Macular edema along with macular ischemia is responsible for decreased visual acuity in central retinal vein occlusion. Bevacizumab (Avastin, Genentech) blocks vascular endothelial growth factor (VEGF) induced hyperpermeability of blood vessels. In this prospective case series we investigated the efficacy of anti-VEGF treatment in reduction of central retinal thickness (CRT) and improvement in visual acuity (VA). 25 patients were followed up for 12 months and treated monthly with intravitreal bevacizumab. VA and CRT were measured at each visit. Treatment was discontinued as the peak improvement of either parameter was reached and reinstituted in case of deterioration/recurrence of edema. Study endpoints included: VA using ETDRS charts, CRT and number of injections at 12 months. Mean VA from all 25 patients increased by 3.1logMAR lines (p<0.05 compared to baseline). The improvement of VA after bevacizumab injection was in correlation with a decrease in CRT. In subgroup analyses, patients receiving bevacizumab injection within the first 3 months after CRVO showed an average VA gain of 4.2 logMAR lines. Mean of 4.5 injections was needed to control the disease during the follow-up period. Bevacizumab treatment was effective in VA and reducing CRT. It appears from subgroup analysis that initiation of treatment early in the course of disease produced better functional outcome. Several injections were needed to control the disease. Regular OCT examinations and retreatment are advised in order to maintain initially reached VA.